
Bispecific and trispecific antibodies show efficacy in multiple myeloma, moving into earlier lines of therapy.
Olivia Main, MD is the chief fellow at NYU Grossman Long Island School of Medicine, Perlmutter Cancer Center in New York, NY.

Bispecific and trispecific antibodies show efficacy in multiple myeloma, moving into earlier lines of therapy.